Approval · Notice of Compliance 36463 · 2025
JAMP RISPERIDONE TABLETS: Notice of Compliance 36463
Issued December 2, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36463
- Date
- December 2, 2025
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- PMS-RISPERIDONE (Pharmascience Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JAMP RISPERIDONE TABLETS | 02563320 | Marketed |
| JAMP RISPERIDONE TABLETS | 02563339 | Marketed |
| JAMP RISPERIDONE TABLETS | 02563347 | Marketed |
| JAMP RISPERIDONE TABLETS | 02563355 | Approved |
| JAMP RISPERIDONE TABLETS | 02563363 | Marketed |
| JAMP RISPERIDONE TABLETS | 02563371 | Approved |
Medicinal ingredients
- RISPERIDONE 0.25 MG per TAB
- RISPERIDONE 0.5 MG per TAB
- RISPERIDONE 1 MG per TAB
- RISPERIDONE 2 MG per TAB
- RISPERIDONE 3 MG per TAB
- RISPERIDONE 4 MG per TAB